Table 2 List of metabolites with the strongest associations with CHD.

From: Investigation of novel metabolites potentially involved in the pathogenesis of coronary heart disease using a UHPLC-QTOF/MS-based metabolomics approach

Metabolite

Super-pathway

Sub-pathway

Multiple linear regression analysis

Logistic regression analysis

Controls

CHD cases

↑/↓

OR (95% CI)a

P valuec

βa

95% CIa

P valueb

Palmitic acid

Fatty acids and conjugates

Saturated fatty acids

Ref.

0.205

(0.105,0.304)

3.64E-05

↑

7.237(2.39,21.912)

1 × 10−4

Linoleic acid

Fatty acids and conjugates

Unsaturated fatty acids

Ref.

0.133

(0.065,0.2)

7.67E-05

↑

6.133(2.367,15.893)

5 × 10−4

4-Pyridoxic acid

Pyridines and derivatives

Pyridinecarboxylic acids

Ref.

0.142

(0.071,0.212)

9.24E-05

↑

4.879(2.158,11.035)

2 × 10−4

Phosphatidylglycerol (20:3/2:0)

Glycerophospholipids

Phosphatidylglycerols

Ref.

0.287

(0.145,0.43)

7.65E-05

↑

3.938(1.891,8.204)

1 × 10−4

Carnitine (14:1)

Quaternary ammonium salts

Carnitines

Ref.

0.332

(0.187,0.477)

6.39E-06

↑

3.379(1.913,5.967)

<1 × 10−4

Lithocholic acid

Steroids and steroid derivatives

Bile acids, alcohols and derivatives

Ref.

0.224

(0.112,0.336)

6.78E-05

↑

2.791(1.74,4.477)

3 × 10−4

  1. aThe models are adjusted for age, sex, body mass index (BMI), hypertension, diabetes, hyperlipidaemia, family history of CHD, smoking and metabolite batch. bConservative Bonferroni correction to a significant threshold of 8.2 × 10−5 (0.05/611) was performed. cA P value < 0.05 was considered statistically significant. The arrows ↑/↓, respectively, indicate an increase or a decrease of the metabolite levels in the plasma of CHD patients compared to those of control subjects.
Back to article page